006280.KS - GC Biopharma Corp.

KSE - KSE Delayed price. Currency in KRW
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
1,711,312,740
1,711,312,740
1,537,825,750
1,504,115,279
1,369,709,727
Cost of revenue
1,129,508,276
1,129,508,276
1,017,232,478
1,063,488,669
997,394,419
Gross profit
581,804,463
581,804,463
520,593,272
440,626,609
372,315,308
Operating expenses
Research development
191,347,000
191,347,000
146,030,000
137,987,000
126,673,000
Selling general and administrative
165,070,797
165,070,797
169,126,651
145,241,084
112,271,768
Total operating expenses
500,540,797
500,540,797
446,857,651
390,342,084
332,020,768
Operating income or loss
81,263,666
81,263,666
73,735,621
50,284,525
40,294,540
Interest expense
18,392,691
18,392,691
12,501,000
10,354,000
9,608,680
Income before tax
85,727,860
85,727,860
172,559,286
104,473,503
-6,141,515
Income tax expense
16,313,075
16,313,075
35,609,407
15,365,726
5,145,885
Income from continuing operations
69,414,785
69,414,785
136,949,879
89,107,777
-11,287,400
Net income
65,453,134
65,453,134
123,211,806
81,048,858
-3,637,552
Net income available to common shareholders
65,453,134
65,453,134
123,211,806
81,048,858
-3,637,552
Basic EPS
-
-
10.80k
7.10k
-319.00
Diluted EPS
-
-
10.80k
7.10k
-319.00
Basic average shares
-
-
11,413
11,414
11,403
Diluted average shares
-
-
11,413
11,414
11,403
EBITDA
-
169,216,551
240,964,286
163,618,503
50,133,165